Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2016
At a glance
- Drugs TRC 102 (Primary) ; Fludarabine
- Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 23 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Sep 2015, according to ClinicalTrials.gov record.